Risk factor
Very high price volatility
Profitability factor
Greatly overvalued vs peers
About
BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI (developed as BXCL501)...
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers.
Target Price
The average target price of BTAI is 15 and suggests 877% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increas
Buy
Sell